False Human Immunodeficiency Virus Test Results Associated with Rheumatoid Factors in Rheumatoid Arthritis△

Yun-chun Li, Fan Yang, Xiao-yun Ji, Zhong-jun Fang, Jun Liu, and Yue Wang

Department of Laboratory Center, Shanghai Guanghua Hospital of Integrative Medicine, Shanghai 200052, China

HUMAN immunodeficiency virus (HIV) remains one of the most serious challenges to health worldwide. Approximately half of the infected people were under the age of 25.1,2Immunoassay- based serological tests for HIV have enabled simple and rapid detection of infection and have been widely implemented as screening tools for both diagnosis and epidemiological monitoring.2In this study, we attempted to identify the immunological factors associated with the false-positive HIV screening results in rheumatoid arthritis (RA).

PATIENTS AND METHODS

Patient selection

100 RA patients were selected randomly between January 2012 and February 2013, aged 32 to 67 years, including 79 females and 21 males. The patients completed questionnaire and clinical data. The mean age of the patients was 49.5±16.5 years. Rheumatoid factors (RF) and anti-CCP antibody titers were determined using enzyme-linked immunosorbent assay (ELISA) kits (AESKU. DIAGNOSTICS, Wendelsheim, Germany). According to their immunological factors titers, RA cases enrolled into this study were classified into two groups: low titer group (RF-IgA, RF-IgG, and RF-IgM <18 U/ml, anti-CCP <25 U/ml), and high titer group (RF-IgA, RF-IgG, and RF-IgM >300 U/ml, anti-CCP > 500 U/ml).

HIV screening methods

HIV screening was performed with electrochemilumines- cence immunoassay (ECLIA, Roche Diagnostics Gmbh, Penzberg, Germany) detecting both HIV-1 p24 antigen, HIV-1 and HIV-2 antibodies, and ELISA (Wantai, Beijing) and colloidal gold method (SD Biosensor, Suwon-si, Korea) detecting only HIV-1 and HIV-2 antibodies. The specimens with positive results were sent to the Center for Disease Control for confirmation by Western blotting. False-positive was considered if screening results were positive and the confirmation results were negative. The patients were interviewed about their sexual behavior and assessed based on signs and symptoms of sexually transmitted infections.

Statistical analysis

The analysis was restricted to individuals of whom complete clinical data were available. Data were processed using SPSS 13.0 software. Categorical data were expressed as frequencies, and compared using χ2test. P<0.05 was considered statistically significant.

RESULTS

Positive rates detected by ECLIA and ELISA

The positive rate of HIV screening by ECLIA was higher than that by ELISA and colloidal gold method in RA (16% versus 0%, P<0.01). 16 of the 100 samples were positive as determined by ECLIA, but ELISA and colloidal gold method presented negative results. The 16 ECLIA positive samples were examined with Western blotting. 13 of which had unconfirmed results. The 13 samples were re-tested after one month, 10 of which produced negative results, and the other 3 were still given unconfirmed results. Three months later, the 3 samples presented negative results as well. The 16 cases all had false-positive results as confirmed by Western blotting.

Association of immunological factors titters with HIV false-positivity in RA

The incidences of positive HIV result determined by ECLIA in different immunological factors groups were 2.7% (1/37) in RF-IgM<18 U/ml group, 32.4% (11/34) and 13.6% (3/22) in RF-IgM >300 U/ml and RF-IgG >300 U/ml group (Table 1). Meanwhile, the positive rate in anti-CCP <25 U/ml and >500 U/ml groups were 4.7% (2/43) and 24.6% (14/57) (Table 2). The false-positive rate of HIV screening was associated with antibody titers of RF-IgG, RF-IgM, RF-IgA and CCP-IgG in RA (P<0.01).

Table 1. Human immunodeficiency virus (HIV) testing results by electrochemiluminescence immunoassay in groups stratified by rheumatoid factor (RF) titer [n (%)]

Table 2. HIV testing results by electrochemiluminescence immunoassay in groups stratified by anti-CCP titer [n (%)]

DISCUSSION

Testing for HIV was begun in 1985 with the introduction of the enzyme immunoassay. Different screening methods including ELISA, ECLIA, and colloidal gold method have been developed, having varying sensitivity and specificity.3,4

ECLIA detects both HIV-1 p24 antigen, HIV-1 and HIV-2 antibodies, while ELISA and colloidal gold method detect only HIV-1 and HIV-2 antibodies.4,5In this study, the positive rate of HIV tests by ECLIA was higher than that by ELISA and colloidal gold method in RA. In the 16 cases with positive results submitted for confirmation by the Center for Disease Control using Western blotting, 13 were uncertain, of whom 10 had negative results in the reexamination one month later, and the other 3 were negative after 3 months by confirmatory testing. Furthermore, among the RA patients, we observed an association between false-positive results and specific immune factors, especially increased titers of RF-IgG, RF-IgM, and anti-CCP antibody. The false-positive rates in RF-IgG<18 U/ml group, RF-IgM<18 U/ml group, and anti-CCP<25 U/ml group were significantly lower than those in RF-IgG>300 U/ml group, RF-IgM>300 U/ml group, and anti-CCP>500 U/ml group.

RF is an antibody against the Fc portion of immunoglobulin G and is associated with autoimmune diseases, such as RA. However, it can also be produced in individuals with viral, bacterial, and other parasitic infections.5,6RA patients often produce auto-antibodies against proteins and peptides containing citrulline. Citrulline is generated in an inflammatory environment through modification of arginine by peptidylarginine deiminase. Anti-CCP antibody is found in serum up to 10 years before the onset of joint symptoms in patients who later develop RA and may appear somewhat earlier than RF.7A positive anti-CCP antibody test result is more consistent with early or even preclinical RA, since this test, unlike RF testing, is generally negative in the setting of infection. We speculated that the mechanisms of the reactivity with HIV p-24 was antigenic mimicry between self-epitopes, such as anti-CCP antibody and the RF-Fc portion of immunoglobulin G.

This study investigated the possible mechanisms of false positivity observed in HIV screening with ECLIA in RA patients. While the rate of false-positive results is of considerable concern, we believe that this problem is not restricted to ECLIA. Further research on the cross-reactivity of HIV diagnostic tests with RA is warranted. Several studies have suggested that ECLIA assay is both highly sensitive and specific.8-10From the study we can also deduce that ECLIA detecting is more sensitive than ELISA and colloidal gold method with rheumatoid samples. While specificity should be improved when tests are applied in combination, the high rate of false-positivity associated with ECLIA assay may lead to a considerable rise in the cost of testing, since positive test results by a particular assay require con- firmation when that assay is used as part of a testing method.

This study had several limitations. First of all, it was difficult to disentangle the independent effects of each immunological factor. Second of all, this was a cross- sectional analysis, so we cannot determine the causality of the associations observed. A large proportion of the immunological factors were associated with false-positive results, and the causes of false-positive HIV screening result may vary with methods. In addition, this study cannot clarify if the same factors of false-positive ECLIA result apply to other HIV tests. Further studies are needed to confirm our findings, elucidate the immunology mechanisms for increased HIV false-positive results screened by ECLIA in RA patients.

The authors of this article thank Rong Xv for immunological guidance, statistical assistance, and interpretation of the assay results for this study.

1. Porter L, Hao L, Bishai D, et al. HIV status and union dissolution in sub-Saharan Africa: the case of Rakai, Uganda. Demography 2004;41:465-82.

2. Hecht FM, Busch MP, Rawal B, et al. Use of laboratory tests and clinical symptoms for identification of primary HIV infection. AIDS 2002;16:1119-29.

3. van Binsbergen J, Siebelink A, Jacobs A, et al. Improved performance of seroconversion with a 4th generation HIV antigen/antibody assay. J Virol Methods 1999;82:77-84.

4. Gray RH, Makumbi F, Serwadda D, et al. Limitations of rapid HIV-1 tests during screening for trials in Uganda: diagnostic test accuracy study. BMJ 2007 [cited 2013 Jul 01]; 335:188. Available from: http://www.bmj.com/ content/335/7612/188?view=long&pmid=17545184.

5. Grobusch MP, Alpermann U, Schwenke S, et al. False- positive rapid tests for malaria in patients with rheumatoid factor. Lancet 1999; 353:297.

6. Newkirk MM. Rheumatoid factors: what do they tell us? J Rheumatol 2002;29:2034-40.

7. Dubucquoi S, Solau-Gervais E, Lefranc D, et al. Evaluation of anti-citrullinated filaggrin antibodies as hallmarks for the diagnosis of rheumatic diseases. Ann Rheum Dis 2004;63: 415-9.

8. Ly TD, Laperche S, Brennan C, et al. Evaluation of the sensitivity and specificity of six HIV combined p24 antigen and antibody assays. J Virol Methods 2004;122:185-94.

9. Mylonakis E, Paliou M, Lally M, et al. Laboratory testing for infection with the human immunodeficiency virus: established and novel approaches. Am J Med 2000; 109:568-76.

10. Talal N, Garry RF, Schur PH, et al. A conserved idiotype and antibodies to retroviral proteins in systemic lupus erythematosus. J Clin Invest 1990; 85:1866-71.